期刊
LAB ON A CHIP
卷 22, 期 7, 页码 1374-1385出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d1lc00931a
关键词
-
类别
资金
- National Science Foundation (NSF) [1919438]
- American Heart Association (AHA) Predoctoral Fellowship [20PRE34990041]
- Clifford D. Clark Diversity Fellowship
- LSAMP Bridge
- Directorate For Engineering
- Div Of Civil, Mechanical, & Manufact Inn [1919438] Funding Source: National Science Foundation
A three-dimensional microfluidic device was developed to simulate the characteristics of calcific aortic valve disease. The presence of high shear stress and endothelial cells was found to contribute to the formation of calcified nodules.
Calcific aortic valve disease (CAVD) is an active pathobiological process leading to severe aortic stenosis, where the only treatment is valve replacement. Late-stage CAVD is characterized by calcification, disorganization of collagen, and deposition of glycosaminoglycans, such as chondroitin sulfate (CS), in the fibrosa. We developed a three-dimensional microfluidic device of the aortic valve fibrosa to study the effects of shear stress (1 or 20 dyne per cm(2)), CS (1 or 20 mg mL(-1)), and endothelial cell presence on calcification. CAVD chips consisted of a collagen I hydrogel, where porcine aortic valve interstitial cells were embedded within and porcine aortic valve endothelial cells were seeded on top of the matrix for up to 21 days. Here, we show that this CAVD-on-a-chip is the first to develop human-like calcified nodules varying in calcium phosphate mineralization maturity resulting from high shear and endothelial cells, specifically di- and octa-calcium phosphates. Long-term co-culture microfluidic studies confirmed cell viability and calcium phosphate formations throughout 21 days. Given that CAVD has no targeted therapies, the creation of a physiologically relevant test-bed of the aortic valve could lead to advances in preclinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据